11 results about "Hla molecules" patented technology

This invention relates to T-cell receptors (TCRs) targeting the cancer / testis antigens NY-ESO-1 and CT83 presented by various HLA molecules. Preferred TCRs of this invention are derived from human T cells and exhibit high affinity and high antigen specificity both in vitro and in vivo. Furthermore, this invention also relates to the regulation of TCR-T and CAR-T cell signaling and their functional persistence in cancer immunotherapy.

The present application relates to the technical field of tumor immunotherapy, and particularly relates to HLA-A*11:01 restricted neoantigen peptides based on malignant pleural effusion tumor cells and application thereof. The present application obtains tumor neoantigen polypeptides by separating and screening from malignant pleural effusion of lung cancer patients, the amino acid sequence of the neoantigen polypeptides is shown in any one of SEQ ID NO. 1-9; the tumor neoantigen polypeptides have high affinity with HLA molecules, can stimulate tumor-specific T cells, and can be used as a target for tumor clinical treatment or diagnosis. The present application further provides a method for separating and screening tumor neoantigen polypeptides, which solves the problem that the neoantigen of non-surgical treatment patients cannot be obtained, and provides an effective method for development of tumor neoantigen polypeptides.

The present application relates to the technical field of tumor immunotherapy, and particularly relates to a tumor neoantigen polypeptide and a method for isolating and screening the same. The amino acid sequence of the tumor neoantigen polypeptide is shown in SEQ ID NO. 1, 2, 3 or 4. The tumor neoantigen polypeptide has high affinity with HLA molecules, can induce tumor-specific T cells, and further produce an immune response targeting tumor cells. The tumor neoantigen polypeptide can be used as a target for tumor clinical treatment or diagnosis, and has good application prospect in tumor immunotherapy. The method for isolating and screening the tumor neoantigen polypeptide provided by the present application solves the problem that the existing method cannot obtain neoantigens of patients who are not treated by surgery, and provides an effective method for developing tumor neoantigen polypeptides.

The present application relates to the technical field of tumor immunotherapy, and particularly relates to HLA-restricted neoantigen polypeptides based on malignant ascites tumor cells and application thereof. The present application provides cholangiocarcinoma neoantigen polypeptides, and the amino acid sequence of the neoantigen polypeptides is shown as SEQ ID NO. 1, 2 or 3. The present application obtains tumor neoantigen polypeptides from cholangiocarcinoma patient malignant ascites through separation and screening, the neoantigen polypeptides have high affinity with HLA molecules, can stimulate tumor-specific T cells, and further generate immune response targeting tumor cells, and can be used as a target for tumor clinical treatment or diagnosis, and has good application prospect in tumor immunotherapy.

The present disclosure is directed to methods of modifying an HLA-binding pocket in an HLA molecule in a subject. Some aspects are directed to HLA molecules comprising a modified HLA-binding pocket, where the HLA molecule has increased affinity for a peptide, e.g., an antigen. Other aspects are directed to compositions comprising the same and methods of using the same.

The present application relates to the technical field of tumor immunotherapy, and particularly relates to HLA-restricted neoantigen polypeptide based on malignant ascites tumor cells and application thereof. The present application provides a cholangiocarcinoma neoantigen polypeptide, and an amino acid sequence of the neoantigen polypeptide is shown as SEQ ID NO. 3. The present application obtains a tumor neoantigen polypeptide by separating and screening from malignant ascites of a cholangiocarcinoma patient, the neoantigen polypeptide has high affinity with HLA molecules, can stimulate tumor-specific T cells to produce, and further produce an immune response targeting tumor cells, and can be used as a target point for clinical treatment or diagnosis of tumors, and has a good application prospect in tumor immunotherapy.

The application belongs to the technical field of immunobiology, and particularly relates to a Ewing's sarcoma antigen peptide and application thereof. The Ewing's sarcoma antigen peptide provided by the application is based on the etiological gene fusion mutation of Ewing's sarcoma, high-frequency fusion gene mutations in the human population are detected by using second-generation sequencing data, and the optimal Ewing's sarcoma antigen peptide obtained by further analysis and prediction. The Ewing's sarcoma antigen peptide is a fusion gene neoantigen, the overlap rate of the Ewing's sarcoma antigen peptide with patients can be as high as 100%, and the Ewing's sarcoma antigen peptide not only has high bioinformatics frequency, but also has high affinity with HLA molecules, and has the potential of specific recognition of tumor cells. In addition, it is verified by immunogenicity experiments that the Ewing's sarcoma antigen peptide has good immunogenicity and immunoprotective power, and the Ewing's sarcoma antigen peptide has great market value for the development of a vaccine for preventing and / or treating Ewing's sarcoma.

The invention belongs to the technical field of immunobiology, and particularly relates to an Ewing's sarcoma antigen peptide and application thereof. The Ewing's sarcoma antigen peptide provided by the invention is an optimal Ewing's sarcoma antigen peptide obtained by detecting high-frequency fusion gene mutation in people by utilizing next-generation sequencing data on the basis of Ewing's sarcoma pathogenesis-gene fusion mutation and further analyzing and predicting. The Ewing's sarcoma antigen peptide is a fusion gene new antigen, the overlapping rate of the Ewing's sarcoma antigen peptide and a patient can reach up to 100%, and meanwhile, the Ewing's sarcoma antigen peptide not only has bioinformatics high frequency, but also has high affinity with HLA molecules, and has the potential of specifically recognizing tumor cells. Besides, an immunogenicity experiment verifies that the Ewing's sarcoma antigen peptide has good immunogenicity and immune protection capacity, and the Ewing's sarcoma antigen peptide has great market value when being used for preparing vaccines for preventing and / or treating Ewing's sarcoma.

This invention relates to the field of tumor immunotherapy technology, and more particularly to HLA-restricted neoantigen peptides based on malignant ascites tumor cells and their applications. This invention provides a cholangiocarcinoma neoantigen peptide, the amino acid sequence of which is shown in SEQ ID NO.3. This invention isolates and screens tumor neoantigen peptides from malignant ascites of cholangiocarcinoma patients. These neoantigen peptides have a high affinity for HLA molecules, can stimulate the production of tumor-specific T cells, and thus generate an immune response targeting tumor cells. They can serve as targets for clinical treatment or diagnosis of tumors and have promising applications in tumor immunotherapy.

This invention relates to the field of tumor immunotherapy technology, and more particularly to HLA-restricted neoantigen peptides based on malignant ascites tumor cells and their applications. This invention provides a cholangiocarcinoma neoantigen peptide, the amino acid sequence of which is shown in SEQ ID NO.2. This invention isolates and screens tumor neoantigen peptides from malignant ascites of cholangiocarcinoma patients. These neoantigen peptides have a high affinity for HLA molecules, can stimulate the production of tumor-specific T cells, and thus generate an immune response targeting tumor cells. They can serve as targets for clinical treatment or diagnosis of tumors and have promising applications in tumor immunotherapy.

The present disclosure provides modified HLA molecules, and methods of using the same to induce or enhance cytotoxicity, the molecules comprising an alpha chain and a beta chain, wherein both chains comprise one or more substituted cysteines that pair to form disulfide bonds, and wherein the modified HLA molecules are optionally further conjugated to an Fc domain at the 3' end.